A familial Alzheimer's genetic panel tests three genes — APP, PSEN1 and PSEN2 — in which a single inherited variant causes early-onset Alzheimer's disease directly, and it is accurate for what it looks at while answering far less than most people expect. It is not a general test of your Alzheimer's risk, it is not a diagnosis, and under published practice guidelines it is meant to be ordered through genetic counseling rather than requested on your own before a memory clinic appointment. That last point shapes what you should actually do between now and the visit. For almost everyone, the useful preparation is not a panel: it is a written symptom timeline, a complete medication list, and a family history detailed enough for the clinic to judge whether genetic testing belongs in your case at all.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the three-gene panel tests, and how rare those variants are
- Who qualifies, and why you probably cannot simply order it
- What a result does and does not settle
- The one genetic test that now changes treatment
- Decide the insurance question before you test
- What to bring to the memory clinic appointment
- Frequently Asked Questions
What the three-gene panel tests, and how rare those variants are
The genes are APP on chromosome 21, PSEN1 on chromosome 14 and PSEN2 on chromosome 1. They are called deterministic, meaning a pathogenic variant in one of them causes Alzheimer's disease rather than nudging the odds. Inheritance is autosomal dominant: a parent with the variant has a 50% chance of passing it to each child. The scale matters before you order anything.
According to the National Institute on Aging's Alzheimer's disease genetics fact sheet, fewer than 10% of all people with Alzheimer's develop symptoms before age 65, and only 10–15% of those early-onset cases trace to these three genes. A familial panel is therefore the right test for a small, specific group of families — typically those where dementia has appeared in multiple generations in people's forties or fifties. APOE is a different kind of gene and a common source of confusion. APOE ε4 is a susceptibility variant: it raises risk without determining the outcome, and it is not part of a familial Alzheimer's panel.
Who qualifies, and why you probably cannot simply order it
Clinical guidance is unusually firm here. The joint practice guideline from the American College of Medical Genetics and the National Society of Genetic Counselors, published in Genetics in Medicine in 2011, states that testing for early-onset autosomal dominant Alzheimer's should take place only within genetic counseling supported by someone expert in the condition. For a relative who has no symptoms and wants predictive testing, the guideline recommends following the Huntington disease protocol — a structured, multi-session process built for results that cannot be acted on medically.
Insurers reflect that structure. Blue Cross NC's medical policy on genetic testing for familial Alzheimer's disease covers APP, PSEN1 and PSEN2 testing in defined situations only: The same policy requires formal genetic counseling beforehand, and excludes testing of children, testing for late-onset Alzheimer's, and testing ordered only to confirm a diagnosis a clinician has already made. Other plans vary in wording, but the shape is consistent — so a panel you buy ahead of your appointment may well be one you pay for yourself.
- a family history of autosomal dominant early-onset dementia
- a first-degree relative with an identified mutation in one of the three genes
- a patient with symptoms and suspected early-onset disease
What a result does and does not settle
A pathogenic variant found in a symptomatic person explains the cause of their disease and tells relatives that a specific, testable variant runs in the family. That is real information, and for some families it ends years of uncertainty. A negative result is weaker than it feels. The ACMG/NSGC guideline notes that the known genes do not exhaust the picture: other susceptibility, deterministic and protective genes very likely exist and are currently unidentified. A clear panel removes three known causes; it does not remove risk.
The same guideline cites an average lifetime Alzheimer's risk of 10–12% as the backdrop every result sits against. Consumer genetic reports carry their own limits. The FDA authorized 23andMe's APOE ε4 report through de novo review, and that authorization is explicit that the report indicates only whether a result is linked to higher risk — it does not describe a person's overall chance of developing Alzheimer's disease. Across its direct-to-consumer authorizations the agency has repeatedly said such tests diagnose no condition and that results should be confirmed by independent clinical testing before any medical decision. An Ambry Genetics study published in Genetics in Medicine in 2018 found variants flagged as increased-risk in consumer raw data that multiple clinical laboratories classified as benign. Raw-data interpretation from third-party tools is the weakest link of all.
The one genetic test that now changes treatment
APOE genotyping has crossed from risk information into prescribing. The label for Leqembi (lecanemab), an anti-amyloid antibody, instructs that ApoE ε4 testing be performed before starting treatment to inform the risk of ARIA — amyloid-related imaging abnormalities, brain swelling or small bleeds visible on MRI. The label notes that ε4 homozygotes, people carrying two copies and roughly 15% of Alzheimer's patients, have higher rates of both symptomatic and serious ARIA. Two details are worth carrying into the clinic.
The label says prescribers should discuss genotype-specific ARIA risk before testing, so the conversation is meant to come first. It also confirms that patients without a known genotype may still be treated — testing informs the decision rather than gating it. This is a reason to let the clinic order APOE if anti-amyloid treatment is on the table, rather than arriving with a consumer report. A clinical-laboratory result goes in the record and can be acted on; a consumer report generally has to be repeated.
Decide the insurance question before you test
The Genetic Information Nondiscrimination Act bars health insurers and employers from discriminating on genetic information, and that protection extends to Medicare, Medicaid, the Federal Employees Health Benefits Program and the Veterans Health Administration. The National Human Genome Research Institute's overview of genetic discrimination is equally clear about the gap: GINA provides no protection for life insurance, disability insurance or long-term care insurance. For a familial Alzheimer's panel that gap is the practical one.
A deterministic result in a healthy adult in their thirties is exactly the information those three products price on, and underwriting questions typically ask what testing you have had. The sequence that protects you is straightforward: settle any life, disability or long-term care coverage you want, then test. A genetic counselor will raise this, which is one more argument for testing through a counseling pathway rather than independently.
What to bring to the memory clinic appointment
The visit itself rewards paperwork more than genetics. The Alzheimer's Association's guidance on visiting your doctor for memory loss asks patients to arrive with specific material: The clinician will ask whether relatives had Alzheimer's or other dementias, so build that answer in advance: who, their relationship to the patient, their age at first symptoms, and what the diagnosis was called at the time.
Age at onset is the detail that drives the genetics decision, and it is the one families most often have to go looking for. Bring any genetic testing you have already had, including consumer reports, and say plainly that it was direct-to-consumer. Then let the clinic decide whether a familial panel belongs in the workup — a decision it can make far better after that visit than you can before it.
- a written list of changes in memory, mood and behavior, with roughly when each began
- current and past medical problems
- every medication container, or a complete list with dosages, including over-the-counter drugs and supplements
- your written questions, in priority order
- a care partner — someone who has observed the changes and can describe them
Frequently Asked Questions
Should I get a familial panel before my first memory clinic visit?
In almost all cases, no. Practice guidance places the test inside genetic counseling, insurers commonly require counseling first, and the clinic's assessment is what establishes whether early-onset autosomal dominant disease is plausible in your family at all.
My consumer test reported one APOE ε4 copy. Does that mean I will develop Alzheimer's?
No. The FDA's authorization of that report states it indicates only whether a result is linked to higher risk, not a person's overall chance of developing the disease. It is also not a diagnosis, and the agency advises confirming consumer results with clinical testing before medical decisions.
Can my children be tested?
Testing of children is specifically excluded under insurer policy for familial Alzheimer's genes, and predictive testing of asymptomatic relatives is recommended to follow the Huntington disease counseling protocol — a process designed for consenting adults.
